FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004704417> ?p ?o ?g. }

• W2004704417 endingPage "1452" @default.
• W2004704417 startingPage "1446" @default.
• W2004704417 abstract "Novel prognostic biomarkers and therapeutic strategies are urgently required for malignant melanoma. Ecto-5-prime-nucleotidase (NT5E; CD73) overexpression has been reported in several human cancers. The mechanism(s) underlying deregulated expression and the clinical consequences of changes in expression are not known.We used RT-PCR, qPCR, methylation-specific PCR and pyrosequencing to analyse expression and regulation of NT5E in malignant melanoma cell lines and primary and metastatic melanomas.NT5E is subject to epigenetic regulation in melanoma. NT5E mRNA is downregulated by methylation-dependent transcriptional silencing in the melanoma cell lines SKMel2, SKMel23, WM35, Mel501, Mel505 and C81-61 and expression is reactivated by azacytidine. In contrast, the CpG island is unmethylated and the gene expressed in cultured normal melanocytes. In clinical cases of melanoma, methylation in the NT5E CpG island occurs in both primary and metastatic melanomas and correlates with transcriptional downregulation of NT5E mRNA. Relapse with metastatic disease, particularly to the visceral sites and brain, is more common in primary melanomas lacking NT5E methylation. Primary melanomas with methylation in NT5E show limited metastatic potential or more commonly metastasise predominantly to nodal sites rather than viscera and brain (P=0.01).Deregulation of NT5E expression in melanoma occurs via epigenetic changes in the NT5E CpG island. Confirmation of our results in larger clinical series would support the candidacy of NT5E as a clinical biomarker in melanoma, which could be applied in both primary and relapsed disease. Inhibition of NT5E may have therapeutic potential in melanoma, particularly in patients with more aggressive disease metastatic to viscera or the brain." @default.
• W2004704417 created "2016-06-24" @default.
• W2004704417 creator A5000836860 @default.
• W2004704417 creator A5002264817 @default.
• W2004704417 creator A5010017616 @default.
• W2004704417 creator A5011010900 @default.
• W2004704417 creator A5015046932 @default.
• W2004704417 creator A5015713295 @default.
• W2004704417 creator A5021264670 @default.
• W2004704417 creator A5022032908 @default.
• W2004704417 creator A5025774787 @default.
• W2004704417 creator A5027846283 @default.
• W2004704417 creator A5043290265 @default.
• W2004704417 creator A5043382789 @default.
• W2004704417 creator A5044662843 @default.
• W2004704417 creator A5045639094 @default.
• W2004704417 creator A5047168527 @default.
• W2004704417 creator A5047470313 @default.
• W2004704417 creator A5049817881 @default.
• W2004704417 creator A5052110718 @default.
• W2004704417 creator A5053878238 @default.
• W2004704417 creator A5056770144 @default.
• W2004704417 creator A5062246308 @default.
• W2004704417 creator A5074488959 @default.
• W2004704417 creator A5085875805 @default.
• W2004704417 date "2012-03-27" @default.
• W2004704417 modified "2023-10-16" @default.
• W2004704417 title "NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity" @default.
• W2004704417 cites W1969179633 @default.
• W2004704417 cites W1996217057 @default.
• W2004704417 cites W2003598902 @default.
• W2004704417 cites W2006385776 @default.
• W2004704417 cites W2009982369 @default.
• W2004704417 cites W2022797399 @default.
• W2004704417 cites W2053908301 @default.
• W2004704417 cites W2060691656 @default.
• W2004704417 cites W2153092839 @default.
• W2004704417 cites W2168786562 @default.
• W2004704417 doi "https://doi.org/10.1038/bjc.2012.95" @default.
• W2004704417 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3326678" @default.
• W2004704417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22454080" @default.
• W2004704417 hasPublicationYear "2012" @default.
• W2004704417 type Work @default.
• W2004704417 sameAs 2004704417 @default.
• W2004704417 citedByCount "79" @default.
• W2004704417 countsByYear W20047044172012 @default.
• W2004704417 countsByYear W20047044172013 @default.
• W2004704417 countsByYear W20047044172014 @default.
• W2004704417 countsByYear W20047044172015 @default.
• W2004704417 countsByYear W20047044172016 @default.
• W2004704417 countsByYear W20047044172017 @default.
• W2004704417 countsByYear W20047044172018 @default.
• W2004704417 countsByYear W20047044172019 @default.
• W2004704417 countsByYear W20047044172020 @default.
• W2004704417 countsByYear W20047044172021 @default.
• W2004704417 countsByYear W20047044172022 @default.
• W2004704417 countsByYear W20047044172023 @default.
• W2004704417 crossrefType "journal-article" @default.
• W2004704417 hasAuthorship W2004704417A5000836860 @default.
• W2004704417 hasAuthorship W2004704417A5002264817 @default.
• W2004704417 hasAuthorship W2004704417A5010017616 @default.
• W2004704417 hasAuthorship W2004704417A5011010900 @default.
• W2004704417 hasAuthorship W2004704417A5015046932 @default.
• W2004704417 hasAuthorship W2004704417A5015713295 @default.
• W2004704417 hasAuthorship W2004704417A5021264670 @default.
• W2004704417 hasAuthorship W2004704417A5022032908 @default.
• W2004704417 hasAuthorship W2004704417A5025774787 @default.
• W2004704417 hasAuthorship W2004704417A5027846283 @default.
• W2004704417 hasAuthorship W2004704417A5043290265 @default.
• W2004704417 hasAuthorship W2004704417A5043382789 @default.
• W2004704417 hasAuthorship W2004704417A5044662843 @default.
• W2004704417 hasAuthorship W2004704417A5045639094 @default.
• W2004704417 hasAuthorship W2004704417A5047168527 @default.
• W2004704417 hasAuthorship W2004704417A5047470313 @default.
• W2004704417 hasAuthorship W2004704417A5049817881 @default.
• W2004704417 hasAuthorship W2004704417A5052110718 @default.
• W2004704417 hasAuthorship W2004704417A5053878238 @default.
• W2004704417 hasAuthorship W2004704417A5056770144 @default.
• W2004704417 hasAuthorship W2004704417A5062246308 @default.
• W2004704417 hasAuthorship W2004704417A5074488959 @default.
• W2004704417 hasAuthorship W2004704417A5085875805 @default.
• W2004704417 hasBestOaLocation W20047044171 @default.
• W2004704417 hasConcept C104317684 @default.
• W2004704417 hasConcept C121608353 @default.
• W2004704417 hasConcept C140173407 @default.
• W2004704417 hasConcept C150194340 @default.
• W2004704417 hasConcept C165864922 @default.
• W2004704417 hasConcept C190727270 @default.
• W2004704417 hasConcept C2777658100 @default.
• W2004704417 hasConcept C41091548 @default.
• W2004704417 hasConcept C502942594 @default.
• W2004704417 hasConcept C54355233 @default.
• W2004704417 hasConcept C86803240 @default.
• W2004704417 hasConceptScore W2004704417C104317684 @default.
• W2004704417 hasConceptScore W2004704417C121608353 @default.
• W2004704417 hasConceptScore W2004704417C140173407 @default.
• W2004704417 hasConceptScore W2004704417C150194340 @default.
• W2004704417 hasConceptScore W2004704417C165864922 @default.

• next